Shuying Shen | Health Professions | Excellence in Innovation Award

Prof. Shuying Shen | Health Professions | Excellence in Innovation Award 

 Zhejiang University | China

Dr. Shuying Shen is a distinguished research fellow at Sir Run Run Shaw Hospital affiliated with the Medical College of Zhejiang University, where she has established a strong research presence in musculoskeletal biology, molecular regulation, and osteoarthritis pathology. She earned her Ph.D. in Biochemistry and Molecular Biology in 2017 and her Bachelor’s degree in Applied Bioscience in 2012, both from Zhejiang University. Dr. Shen’s research has been continuously supported by major competitive grants, including the National Natural Science Foundation of China Excellent Young Scholars Fund, multiple NSFC General Programs, and the Zhejiang Provincial Outstanding Youth Project. Her funded projects focus on elucidating mechanisms of protein post-translational modification, chondrocyte aging, metabolic reprogramming in osteosarcoma, and non-classical regulatory pathways in chondrocyte physiology, reflecting her deep engagement with both degenerative diseases and cancer biology. Dr. Shen has made influential contributions to the understanding of noncoding RNA functions in osteoarthritis progression, osteosarcoma development and metastasis, and organ size regulation. Her work reveals how circular RNAs, microRNAs, and RNA–protein interactions shape cellular senescence, lipid metabolism, autophagy, and energy homeostasis. She has also advanced knowledge on the interplay between metabolic remodeling and epigenetic regulation in cartilage degeneration. Her publications demonstrate innovative approaches combining molecular biology, functional genomics, epigenetics, and translational models to uncover therapeutic targets for osteoarthritis, intervertebral disc degeneration, and malignancies. Dr. Shen has published 87 peer-reviewed papers, including 50 as first or corresponding author, in top-tier journals such as Nature Aging, Science Translational Medicine, Cell Research, Nature Communications, Annals of the Rheumatic Diseases, PNAS, Advanced Science, Molecular Cancer, Bone Research, and Molecular Therapy. Her research has been cited more than 3,000 times, and she holds an H-index of 37, underscoring her strong scientific influence. Through her pioneering discoveries—such as the regulation of chondrocyte senescence by palmitoylation, the role of fatty acid oxidation in osteoarthritis, circRNA-mediated metabolic control, and noncoding RNA networks in osteosarcoma—Dr. Shen has significantly advanced the field of musculoskeletal molecular medicine. Her long-term research goal is to develop novel diagnostic markers and targeted therapies for osteoarthritis and related degenerative diseases through a deeper understanding of RNA regulation, protein modifications, and metabolic homeostasis.

Profile: Scopus

Featured Publications

Wang, K., He, W., Gong, Z., Gao, J., Gao, T., Pan, N., Wu, D., Yang, Y., Li, Z., Zhao, X., Ji, M., & Shen, S. Y. (2025). ZDHHC11-mediated palmitoylation alleviates chondrocyte senescence and serves as a therapeutic target for osteoarthritis. Nature Aging.

Mei, Z., Yilamu, K., Ni, W., Shen, P., Pan, N., Chen, H., Su, Y., Guo, L., Sun, Q., Li, Z., Huang, D., Fang, X., Fan, S., Zhang, H., & Shen, S. Y. (2025). Chondrocyte fatty acid oxidation drives osteoarthritis via SOX9 degradation and epigenetic regulation. Nature Communications, 16(1), 4892.

Gong, Z., Zhu, J., Chen, J., Feng, F., Zhang, H., Zhang, Z., Song, C., Liang, K., Yang, S., Fan, S., Fang, X., & Shen, S. Y. (2023). CircRREB1 mediates lipid metabolism–related senescent phenotypes in chondrocytes through FASN post-translational modifications. Nature Communications, 14(1), 5242.

Li, Z., Zhang, W., Wei, X. Y., Hu, J. Z., Hu, X., Liu, H., Lu, J., Shen, S. Y., & Ji, M. L. (2025). TRIM15 drives chondrocyte senescence and osteoarthritis progression. Science Translational Medicine, 17(791), eadq1735.

Shen, S. Y., Guo, X. C., Yan, H., Lu, Y., Ji, X. Y., Li, L., Liang, T. B., Zhou, D. W., Zhao, J. C., Yu, J. D., Gong, X. G., Zhang, L., & Zhao, B. (2015). A miR-130a–YAP positive feedback loop promotes organ size and tumorigenesis. Cell Research, 25(9), 997–1012.

Shen, S. Y., Wu, Y. Z., Chen, J. X., Xie, Z., Huang, K. M., Wang, G. L., Yang, Y. T., Ni, W. Y., Chen, Z. J., Shi, P. H., Ma, Y., & Fan, S. W. (2019). CircSERPINE2 protects against osteoarthritis by targeting miR-1271 and ETS-related gene. Annals of the Rheumatic Diseases, 78(6), 826–836.

Shen, S. Y., Yang, Y. T., Shen, P. Y., Ma, J., Fang, B., Wang, Q. X., Wang, K. F., Shi, P. H., Fan, S. W., & Fang, X. Q. (2021). circPDE4B prevents articular cartilage degeneration and promotes repair by acting as a scaffold for RIC8A and MID1. Annals of the Rheumatic Diseases, 80(9), 1209–1219.

Shen, S. Y., Liang, Y., Zhao, Y., Hu, Z., Huang, Y., Wu, Y., Liu, Y., Fan, S., Wang, Q., & Xiao, P. (2024). Dietary supplementation of vitamin B1 prevents the pathogenesis of osteoarthritis. Proceedings of the National Academy of Sciences, 121(30), e2408160121.

Nicola Cosentino | Medicine and Dentistry | Breakthrough Research Award

Dr. Nicola Cosentino | Medicine and Dentistry | Breakthrough Research Award

Dr. Nicola Cosentino | Centro Cardiologioco Monzino | Italy

Dr. Nicola Cosentino is a distinguished Italian cardiologist and researcher whose clinical and scientific contributions have significantly advanced the field of cardiovascular medicine. His career reflects a seamless integration of clinical excellence, research innovation, and academic leadership. With extensive expertise in acute coronary syndromes, perioperative cardiology, and intensive cardiac care, Dr. Cosentino has demonstrated a lifelong commitment to improving patient care through evidence-based medicine and cutting-edge research. His dedication is further underscored by his leadership roles within leading medical institutions and international collaborations, which have allowed him to shape both clinical practice and future research directions. Through a holistic approach that combines patient care, translational science, and teaching, Dr. Cosentino stands as a leading figure in cardiology whose work continues to impact patients, students, and the global medical community. His professional journey represents excellence, perseverance, and innovation in cardiovascular healthcare.

Profiles

Scopus
Orcid

Education

Dr. Nicola Cosentino reflects a trajectory of distinction and excellence in the medical sciences. His educational journey began with a diploma from the Classical High School in Italy, where he graduated with the highest honors, demonstrating early intellectual rigor and dedication. He subsequently earned his medical degree from the Sacred Heart Catholic University of Rome, graduating with full honors and recognition for his thesis on eosinophils in coronary atherosclerosis, conducted under the mentorship of world-renowned cardiology experts. He further specialized in cardiology with distinction at the same institution, completing his specialization with highest marks for a thesis on monocyte-derived macrophages in ischemic heart disease. To deepen his scientific expertise, Dr. Cosentino pursued a PhD in Translational Medicine at the University of Milan, consolidating his commitment to bridging laboratory science with clinical practice. His comprehensive educational training represents a balanced blend of clinical mastery and research excellence.

Experience

Dr. Nicola Cosentino has established an outstanding career marked by diverse clinical and leadership roles within some of Italy’s most prestigious medical institutions. His early professional development was shaped at the Centro Cardiologico Monzino, Milan, where he developed a strong clinical foundation in managing acute and chronic ischemic heart diseases, as well as high-risk cardiovascular conditions. Over the years, he has progressed through key roles, including staff cardiologist, head of the Acute Coronary Syndrome Unit, and medical lead manager of the Italian cardiovascular team at AstraZeneca. Most recently, he was appointed head of the Peri-Operative Cardiology Unit at Centro Cardiologico Monzino, where he now leads advanced clinical programs integrating perioperative assessment, risk management, and innovative therapeutic strategies. His professional journey combines patient care, organizational leadership, and scientific guidance, demonstrating a career that consistently bridges cutting-edge cardiology with practical, patient-centered applications in both hospital and industry settings.

Research Interest

Dr. Cosentino are centered on understanding and addressing the mechanisms underlying coronary artery disease and heart failure, both in acute and chronic presentations. His work has focused extensively on identifying novel biomarkers and molecular pathways that influence the diagnosis, prognosis, and management of these conditions. Special emphasis has been placed on investigating the role of diabetes mellitus, renal impairment, and multi-organ involvement in cardiovascular disease progression. His research also explores the clinical significance of myocardial remodeling and inflammation in acute coronary syndromes, as well as the role of advanced cardiovascular monitoring technologies. By integrating molecular science with patient-focused clinical research, Dr. Cosentino continues to contribute valuable insights into translational cardiology. His long-standing dedication has positioned him as a leading voice in precision medicine approaches, aiming to personalize treatment strategies and improve outcomes for patients facing life-threatening cardiovascular events.

Awards & Recognitions

Dr. Cosentino’s research achievements is reflected in his numerous awards and competitive research grants. His early career excellence was acknowledged through support from the Fondazione Umberto Veronesi, funding projects that examined monocyte-derived macrophages and coronary plaque morphology in ischemic heart disease. He was further awarded competitive grants from the Italian Ministry of Health, including the prestigious “Giovani Ricercatori” program for his PROMISE study on myocardial infarction and non-obstructive coronary arteries, and later through a national PNRR project exploring mitochondrial targets for stroke treatment. These recognitions highlight the innovative and impactful nature of his work, aligning with global efforts to improve cardiovascular diagnostics and therapy. Beyond financial grants, he has been entrusted with leadership positions in scientific societies and advisory committees, reflecting confidence in his scientific judgment. Collectively, these awards affirm his role as a rising leader whose contributions hold significant promise for the future of cardiovascular medicine.

Publication Top Notes

Prognostic Impact of Percutaneous Coronary Intervention in Older Patients Hospitalized with Acute Myocardial Infarction: Real-World Findings from the Lombardy Health Database

Journal: Journal of Clinical Medicine 
Authors: Giancarlo Marenzi, Nicola Cosentino, Marta Resta, Claudia Lucci, Alice Bonomi, Filippo Trombara, Michele Della Rocca, Paolo Poggio, Olivia Leoni, Francesco Bortolan et al.

Impact of Prior Statin Therapy on In-Hospital Outcome of STEMI Patients Treated with Primary Percutaneous Coronary Intervention

Journal: Journal of Clinical Medicine 
Authors: Oreste Lanza, Nicola Cosentino, Claudia Lucci, Marta Resta, Mara Rubino, Valentina Milazzo, Monica De Metrio, Filippo Trombara, Jeness Campodonico, José Pablo Werba et al.

Mitochondrial Biomarkers in Patients with ST-Elevation Myocardial Infarction and Their Potential Prognostic Implications: A Prospective Observational Study

Journal: Journal of Clinical Medicine
Authors: Nicola Cosentino; Jeness Campodonico, Marco Moltrasio, Claudia Lucci, Valentina Milazzo, Mara Rubino, Monica De Metrio, Ivana Marana; Marco Grazi, Alice Bonomi et al.

Acute Kidney Injury in Diabetic Patients With Acute Myocardial Infarction: Role of Acute and Chronic Glycemia

Journal: Journal of the American Heart Association 
Authors: Giancarlo Marenzi, Nicola Cosentino, Valentina Milazzo, Monica De Metrio, Mara Rubino, Jeness Campodonico, Marco Moltrasio, Ivana Marana, Marco Grazi, Gianfranco Lauri et al.

Association Between Haptoglobin Phenotype and Microvascular Obstruction in Patients With ST-Segment Elevation Myocardial Infarction: A Cardiac Magnetic Resonance Study

Journal: JACC: Cardiovascular Imaging 
Authors: Gianluca Pontone, Daniele Andreini, Andrea I. Guaricci, Marco Guglielmo, Andrea Baggiano, Giuseppe Muscogiuri, Laura Fusini, Fabio Fazzari, Claudio Berzovini, Annalisa Pasquini et al.

Conclusion

Dr. Nicola Cosentino represents an exemplary candidate for recognition in the field of cardiology. His career is distinguished by a rare combination of clinical mastery, academic excellence, and innovative research. From his early achievements as a top graduate to his leadership roles in hospital cardiology units and industry, he has consistently demonstrated a vision to improve cardiovascular care through science and compassion. His research outputs have shaped understanding of acute coronary syndromes, myocardial remodeling, and multi-organ interactions, with direct implications for clinical practice and patient outcomes. Furthermore, his dedication to education, mentorship, and collaboration within international networks highlights his commitment to shaping the future of cardiovascular medicine. Through his pioneering research, impactful publications, and leadership contributions, Dr. Cosentino embodies the qualities of a transformative clinician-scientist. He stands as an ideal nominee for prestigious recognition, with a career that continues to inspire innovation and excellence in cardiovascular healthcare.

Assoc. Prof. Dr. Jessica Fleming | Molecular Biomarkers | Best Researcher Award

Assoc. Prof. Dr. Jessica Fleming | Molecular Biomarkers | Best Researcher Award

The Ohio State University, United States.

Dr. Jessica L. Fleming, PhD, is an accomplished radiobiologist at the James Comprehensive Cancer Center, The Ohio State University. With over a decade of experience in translational oncology research, she specializes in molecular biomarkers and radiation therapy innovations. Dr. Fleming plays a key role in collaborative clinical and research initiatives, especially in glioma and FLASH radiotherapy. She is also a co-founder and former CEO of the Cap City Biohackers, demonstrating her entrepreneurial edge in biomedical innovation.

Profile

Scopus

🎓 Education

Dr. Fleming earned her PhD in Molecular, Cellular, and Developmental Biology from The Ohio State University in 2012, following a BS in Biology, Cum Laude, from Ashland University in 2006. Her strong academic foundation was supported by multiple fellowships and research opportunities during her undergraduate and graduate studies.

🧪 Experience

Dr. Fleming currently serves as an Associate Radiobiologist at OSU, working with Dr. Arnab Chakravarti. Her journey at OSU began as a graduate student, advancing through postdoctoral research and senior research associate roles. She has led cutting-edge radiobiological studies and was integral to several major clinical protocols. Beyond academia, she was the CEO and Co-Founder of Cap City Biohackers, reflecting her commitment to science outreach and innovation.

🔬 Research Interests

Radiation oncology and molecular oncology, particularly adult gliomas and biomarkers

FLASH radiotherapy, clinical translation, and toxicity modeling

Tumor heterogeneity and resistance mechanisms

Translational research bridging lab discoveries and patient care

🏆 Awards & Honors

🥇 2024 ASTRO Annual Meeting Abstract Award

🏅 Columbus CEO Future 50 Award (2020)

🎖 Best of ASTRO & Basic/Translational Science Abstract Award (2018)

🎓 Alumni Grants for Graduate Research (2012)

🧬 NSF REU Fellow (2005)

🌟 Track & Field Athletic Scholar and Presidential Scholar (2002–2006)

📚 Selected Publications

Here are some of Dr. Fleming’s key publications, with citation and access details:

Fleming JL et al. (2025)Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813Int J Radiat Oncol Biol Phys (Accepted)

Manring HR, Fleming JL et al. (2025)FLASH Radiotherapy: From In Vivo Data to Clinical TranslationHematol Oncol Clin N Am (PMID: 39828472)

Fleming JL, Chakravarti A. (2025)Molecular Biomarkers in Adult Lower-Grade GliomasCancer J, 31(1): e0758. (PMID: 39841423)
Cited by: 2 articles

Kotecha R, Schiff D, Chakravarti A, Fleming JL et al. (2024)Management of IDH-Mutated GliomasJ Clin Oncol, 42(21): 2588-2598. (PMID: 38833641)
Cited by: 15 articles

Becker AP, Becker V, McElroy J, Fleming J et al. (2024)HMGB2 as Biomarker in AstrocytomasCancers (Basel), 16(8): 1516. (PMID: 38672598)
Cited by: 7 articles

Dr. Solomon Jacob | Parasitology | Best Researcher Award

Dr. Solomon Jacob | Parasitology | Best Researcher Award

Federal Ministry of Health, Nigeria.

Dr. Solomon Monday Jacob (JSM) is a seasoned Medical Parasitologist and a Chief Medical Laboratory Scientist at the Federal Ministry of Health, Nigeria. He serves as the Technical Lead for the National Schistosomiasis and Soil-Transmitted Helminthiasis Control Programme, playing a pivotal role in expanding Neglected Tropical Diseases (NTDs) control in Nigeria. With vast experience in malaria, onchocerciasis, lymphatic filariasis, and NTD research, he has contributed significantly to disease prevention strategies. He has published numerous research papers and collaborates with global organizations on healthcare innovations.

Profile

Orcid

🎓 Education

Dr. Solomon Jacob holds a PhD in Medical Laboratory Science with a specialization in Medical Parasitology. His academic journey has equipped him with in-depth knowledge of infectious diseases, epidemiology, and diagnostic techniques. In addition to his doctorate, he has undergone extensive training in Neglected Tropical Diseases (NTD) control programs, focusing on strategies for disease surveillance, prevention, and treatment. His expertise in disease epidemiology has enabled him to contribute significantly to public health initiatives, research projects, and policy development aimed at reducing the burden of NTDs in Nigeria and beyond.

🏢 Professional Experience

Dr. Solomon Jacob is a dedicated Program Officer for Neglected Tropical Diseases (NTDs) at the Federal Ministry of Health, Nigeria, where he plays a crucial role in formulating and implementing national disease control strategies. As a Chief Medical Laboratory Scientist, he leads technical initiatives for the Schistosomiasis & Soil-Transmitted Helminthiasis Control Programme, focusing on innovative approaches to diagnosis, treatment, and eradication efforts.

Beyond his government role, Dr. Jacob serves as a Researcher and Consultant, contributing to significant projects on Malaria, Onchocerciasis, Lymphatic Filariasis, and other NTDs. His work involves operational research, policy advisory, and capacity building to strengthen disease surveillance and control measures. Additionally, he is an Editorial Board Member for renowned scientific journals such as PLoS NTD and Elsevier, furthering his impact in global health research.

🔬 Research Interests

Neglected Tropical Diseases (NTDs) 🦠

Schistosomiasis & Soil-Transmitted Helminthiasis 🏥

Malaria & Vector-Borne Diseases 🦟

Onchocerciasis & Lymphatic Filariasis 🏨

Public Health & Disease Control Strategies

🏆 Awards & Recognitions

Recognized for strategic contributions to NTD control in Nigeria

Lead researcher in multiple operational health projects

Editorial Appointments with PLoS NTD, Elsevier

📚 Selected Publications

Schistosomiasis and Soil Transmitted Helminthiasis Among School-Age Children: Impact of 3–5 Annual Rounds of Mass Drug Administration in Ekiti State, Southwest Nigeria
🗓 2025-03-23 | Journal article | 📖 Tropical Medicine and Infectious Disease
🔗 DOI: 10.3390/tropicalmed10040085
👥 Contributors: Solomon Monday Jacob, Jan-Carel Diehl, Gleb Vdovine, Temitope Agbana, Samuel Popoola, Satyajith Jujjavarapu, David Bell, Akande Oladimeji Ajayi, Joseph O. Fadare, Adebowale F. Akinwumi et al.

Impact of Preventive Chemotherapy on the Prevalence of Schistosomiasis and Soil-Transmitted Helminthiasis Among School-Age Children After 3–5 Effective Rounds of Annual Mass Drug Administration in Ekiti State, Southwest Nigeria
🗓 2025-01-27 | Preprint
🔗 DOI: 10.20944/preprints202501.1916.v1
👥 Contributors: Solomon Monday Jacob, Jan-Carel Diehl, Gleb Vdovine, Temitope Agbana, Samuel Popoola, Satyajith Jujjavarapu, David Bell, Oladimeji Ajayi, Joseph O. Fadare, Adebowale F. Akinwumi et al.

Impact of Praziquantel Mass Drug Administration after Several Rounds on Schistosomiasis Among School-Aged Children in Abuja, Nigeria
🗓 2025-01-22 | Preprint
🔗 DOI: 10.20944/preprints202501.1625.v1
👥 Contributors: Solomon Monday Jacob, Sophie Y. Akinbo, Akinola Stephen Oluwole, Temitope Agbana, Zainab Omoruyi, Michael A. Okungbowa, Diehl Jan-Carel, Fredrick O. Akinbo

Community Mobilisation for Human Sample Collection in Sensitive Communities: Experiences from Granular Mapping of Schistosomiasis and Soil-Transmitted Helminths in Ekiti State, South West, Nigeria
🗓 2024-10-25 | Journal article | 📖 Tropical Medicine and Infectious Disease
🔗 DOI: 10.3390/tropicalmed9110255
👥 Contributors: Temitope Agbana, Omolade Omotade, Moses Aderogba, David Bell, Jacob Solomon, Saheed Animashaun, Peace Alabi, Oladimeji Ajayi, Adebowale Akinwumi, Samuel Popoola et al.

Community Mobilisation for Human Sample Collection in Sensitive Communities: Experiences from Granular Mapping of Schistosomiasis & Soil-Transmitted Helminths in Ekiti State, Nigeria
🗓 2024-09-16 | Preprint
🔗 DOI: 10.20944/preprints202409.1200.v1
👥 Contributors: Temitope Agbana, Omolade Omotade, Moses Aderogba, David Bell, Jacob Solomon, Saheed Animashaun, Peace Alabi, Oladimeji Ajayi, Adebowale Akinwumi, Samuel Popoola et al.